Information Provided By:
Fly News Breaks for December 20, 2016
MGNX
Dec 20, 2016 | 07:03 EDT
SunTrust analyst Peter Lawson initiated MacroGenics with a Buy and a $30 price target saying its DART technology is well positioned to rival CAR T cell therapy in cancer. Lawson would be a buyer of shares ahead of 2017 catalysts that include Enoblituzumab combo data, Phase 1/2 gastric combo data, Phase 1 DART data.
News For MGNX From the Last 2 Days
There are no results for your query MGNX